MENU
+Compare
ZLAB
Stock ticker: NASDAQ
AS OF
Nov 21, 12:09 PM (EDT)
Price
$19.80
Change
-$0.41 (-2.03%)
Capitalization
2.29B

ZLAB Zai Lab Limited Forecast, Technical & Fundamental Analysis

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases... Show more

Industry: #Biotechnology
ZLAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for ZLAB with price predictions
Nov 20, 2025

ZLAB in -5.88% downward trend, falling for three consecutive days on November 18, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ZLAB declined for three days, in of 327 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 50-day moving average for ZLAB moved below the 200-day moving average on October 20, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

The Aroon Indicator for ZLAB entered a downward trend on November 20, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in of 280 cases, the price rose further within the following month. The odds of a continued upward trend are .

ZLAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.952) is normal, around the industry mean (27.115). P/E Ratio (0.000) is within average values for comparable stocks, (51.613). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.036). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (4.931) is also within normal values, averaging (317.729).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ZLAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ZLAB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

ZLAB is expected to report earnings to fall 53.67% to -15 cents per share on March 03

Zai Lab Limited ZLAB Stock Earnings Reports
Q4'25
Est.
$-0.15
Q3'25
Missed
by $0.08
Q2'25
Beat
by $0.37
Q1'25
Beat
by $0.42
Q4'24
Beat
by $0.65
The last earnings report on November 06 showed earnings per share of -33 cents, missing the estimate of -25 cents. With 169.26K shares outstanding, the current market capitalization sits at 2.29B.
A.I. Advisor
published General Information

General Information

a service for cancer & autoimmune treatment

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
4560 Jinke Road
Phone
+86 2161632588
Employees
2175
Web
https://www.zailaboratory.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
KINCX70.16N/A
N/A
Kinetics Internet Adv C
FGEMX133.36N/A
N/A
Fidelity Advisor Communication ServicesM
WHGCX18.86N/A
N/A
Westwood Quality SmallCap Fund C
VELAX17.35N/A
N/A
VELA Large Cap Plus A
IGIFX44.53-0.35
-0.78%
American Funds Intl Gr and Inc F1

ZLAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
-1.22%
ONC - ZLAB
54%
Loosely correlated
-1.27%
IRON - ZLAB
37%
Loosely correlated
-0.44%
BMRN - ZLAB
36%
Loosely correlated
-0.10%
MGTX - ZLAB
35%
Loosely correlated
-2.11%
LEGN - ZLAB
35%
Loosely correlated
-1.59%
More